A number of clinical trials have shown that the presence of signaling pathway biomarkers, like for example ER (estrogen receptor) and Her2/Neu in breast cancer, may differ between primary and metastatic tumors, in up to about half of the cases [5]. Here, ESR1 is linked to breast carcinoma.